Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors

Kyriakos P Papadopoulos, Josep Tabernero, Benjamin Markman, Amita Patnaik, Anthony W Tolcher, Jose Baselga, Weiliang Shi, Coumaran Egile, Rodrigo Ruiz-Soto, A Douglas Laird, Dale Miles, Patricia M LoRusso

Research output: Contribution to journalArticleResearchpeer-review

Abstract

This phase I, first-in-human study evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of SAR245409, an inhibitor of pan-Class I phosphoinositide 3-kinase (PI3K) and mTOR, administered orally once or twice daily in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Eighty-three patients received SAR245409. Doses ranged from 15 to 120 mg twice daily, and 70 to 100 mg once daily. A 3+3 dose-escalation design was used to determine the MTD. Patients were evaluated for adverse events and response. Assessments included pharmacokinetic, pharmacodynamic impact of SAR245409 on PI3K pathway signaling in hair sheath cells, skin and tumor, and characterization of tumor molecular alterations. RESULTS: The MTDs were 50 mg twice daily and 90 mg once daily. The most frequent treatment-related adverse events were nausea (36.1 ), diarrhea (21.7 ), vomiting (19.3 ), and decreased appetite (16.9 ). The most frequent treatment-related grade 3/4 adverse events were increases in alanine aminotransferase (6.0 ) and aspartate aminotransferase (4.8 ). SAR245409 had a relatively short plasma half-life (2.96-7.52 hours). At MTDs, once- and twice-daily regimens yielded similar mean steady-state plasma exposure. A reduction in PI3K and mTORC1/mTORC2 pathway signaling was observed in serial hair sheath cells, skin, and tumor samples. Best response was stable disease in 48 of evaluable patients; seven patients had minor tumor regression. Twelve patients with stable disease were treated for >/=16 weeks. No trend was observed correlating tumor molecular alteration with antitumor activity. CONCLUSION: SAR245409 had a manageable safety profile, demonstrated reduced PI3K and mTORC1/mTORC2 pathway signaling and was associated with clinically relevant stable disease.
Original languageEnglish
Pages (from-to)2445 - 2456
Number of pages12
JournalClinical Cancer Research
Volume20
Issue number9
DOIs
Publication statusPublished - 2014

Cite this

Papadopoulos, Kyriakos P ; Tabernero, Josep ; Markman, Benjamin ; Patnaik, Amita ; Tolcher, Anthony W ; Baselga, Jose ; Shi, Weiliang ; Egile, Coumaran ; Ruiz-Soto, Rodrigo ; Laird, A Douglas ; Miles, Dale ; LoRusso, Patricia M. / Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. In: Clinical Cancer Research. 2014 ; Vol. 20, No. 9. pp. 2445 - 2456.
@article{fb0fe62436d94a38ac32b3795c79b740,
title = "Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors",
abstract = "This phase I, first-in-human study evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of SAR245409, an inhibitor of pan-Class I phosphoinositide 3-kinase (PI3K) and mTOR, administered orally once or twice daily in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Eighty-three patients received SAR245409. Doses ranged from 15 to 120 mg twice daily, and 70 to 100 mg once daily. A 3+3 dose-escalation design was used to determine the MTD. Patients were evaluated for adverse events and response. Assessments included pharmacokinetic, pharmacodynamic impact of SAR245409 on PI3K pathway signaling in hair sheath cells, skin and tumor, and characterization of tumor molecular alterations. RESULTS: The MTDs were 50 mg twice daily and 90 mg once daily. The most frequent treatment-related adverse events were nausea (36.1 ), diarrhea (21.7 ), vomiting (19.3 ), and decreased appetite (16.9 ). The most frequent treatment-related grade 3/4 adverse events were increases in alanine aminotransferase (6.0 ) and aspartate aminotransferase (4.8 ). SAR245409 had a relatively short plasma half-life (2.96-7.52 hours). At MTDs, once- and twice-daily regimens yielded similar mean steady-state plasma exposure. A reduction in PI3K and mTORC1/mTORC2 pathway signaling was observed in serial hair sheath cells, skin, and tumor samples. Best response was stable disease in 48 of evaluable patients; seven patients had minor tumor regression. Twelve patients with stable disease were treated for >/=16 weeks. No trend was observed correlating tumor molecular alteration with antitumor activity. CONCLUSION: SAR245409 had a manageable safety profile, demonstrated reduced PI3K and mTORC1/mTORC2 pathway signaling and was associated with clinically relevant stable disease.",
author = "Papadopoulos, {Kyriakos P} and Josep Tabernero and Benjamin Markman and Amita Patnaik and Tolcher, {Anthony W} and Jose Baselga and Weiliang Shi and Coumaran Egile and Rodrigo Ruiz-Soto and Laird, {A Douglas} and Dale Miles and LoRusso, {Patricia M}",
year = "2014",
doi = "10.1158/1078-0432.CCR-13-2403",
language = "English",
volume = "20",
pages = "2445 -- 2456",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research",
number = "9",

}

Papadopoulos, KP, Tabernero, J, Markman, B, Patnaik, A, Tolcher, AW, Baselga, J, Shi, W, Egile, C, Ruiz-Soto, R, Laird, AD, Miles, D & LoRusso, PM 2014, 'Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors', Clinical Cancer Research, vol. 20, no. 9, pp. 2445 - 2456. https://doi.org/10.1158/1078-0432.CCR-13-2403

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. / Papadopoulos, Kyriakos P; Tabernero, Josep; Markman, Benjamin; Patnaik, Amita; Tolcher, Anthony W; Baselga, Jose; Shi, Weiliang; Egile, Coumaran; Ruiz-Soto, Rodrigo; Laird, A Douglas; Miles, Dale; LoRusso, Patricia M.

In: Clinical Cancer Research, Vol. 20, No. 9, 2014, p. 2445 - 2456.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors

AU - Papadopoulos, Kyriakos P

AU - Tabernero, Josep

AU - Markman, Benjamin

AU - Patnaik, Amita

AU - Tolcher, Anthony W

AU - Baselga, Jose

AU - Shi, Weiliang

AU - Egile, Coumaran

AU - Ruiz-Soto, Rodrigo

AU - Laird, A Douglas

AU - Miles, Dale

AU - LoRusso, Patricia M

PY - 2014

Y1 - 2014

N2 - This phase I, first-in-human study evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of SAR245409, an inhibitor of pan-Class I phosphoinositide 3-kinase (PI3K) and mTOR, administered orally once or twice daily in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Eighty-three patients received SAR245409. Doses ranged from 15 to 120 mg twice daily, and 70 to 100 mg once daily. A 3+3 dose-escalation design was used to determine the MTD. Patients were evaluated for adverse events and response. Assessments included pharmacokinetic, pharmacodynamic impact of SAR245409 on PI3K pathway signaling in hair sheath cells, skin and tumor, and characterization of tumor molecular alterations. RESULTS: The MTDs were 50 mg twice daily and 90 mg once daily. The most frequent treatment-related adverse events were nausea (36.1 ), diarrhea (21.7 ), vomiting (19.3 ), and decreased appetite (16.9 ). The most frequent treatment-related grade 3/4 adverse events were increases in alanine aminotransferase (6.0 ) and aspartate aminotransferase (4.8 ). SAR245409 had a relatively short plasma half-life (2.96-7.52 hours). At MTDs, once- and twice-daily regimens yielded similar mean steady-state plasma exposure. A reduction in PI3K and mTORC1/mTORC2 pathway signaling was observed in serial hair sheath cells, skin, and tumor samples. Best response was stable disease in 48 of evaluable patients; seven patients had minor tumor regression. Twelve patients with stable disease were treated for >/=16 weeks. No trend was observed correlating tumor molecular alteration with antitumor activity. CONCLUSION: SAR245409 had a manageable safety profile, demonstrated reduced PI3K and mTORC1/mTORC2 pathway signaling and was associated with clinically relevant stable disease.

AB - This phase I, first-in-human study evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of SAR245409, an inhibitor of pan-Class I phosphoinositide 3-kinase (PI3K) and mTOR, administered orally once or twice daily in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Eighty-three patients received SAR245409. Doses ranged from 15 to 120 mg twice daily, and 70 to 100 mg once daily. A 3+3 dose-escalation design was used to determine the MTD. Patients were evaluated for adverse events and response. Assessments included pharmacokinetic, pharmacodynamic impact of SAR245409 on PI3K pathway signaling in hair sheath cells, skin and tumor, and characterization of tumor molecular alterations. RESULTS: The MTDs were 50 mg twice daily and 90 mg once daily. The most frequent treatment-related adverse events were nausea (36.1 ), diarrhea (21.7 ), vomiting (19.3 ), and decreased appetite (16.9 ). The most frequent treatment-related grade 3/4 adverse events were increases in alanine aminotransferase (6.0 ) and aspartate aminotransferase (4.8 ). SAR245409 had a relatively short plasma half-life (2.96-7.52 hours). At MTDs, once- and twice-daily regimens yielded similar mean steady-state plasma exposure. A reduction in PI3K and mTORC1/mTORC2 pathway signaling was observed in serial hair sheath cells, skin, and tumor samples. Best response was stable disease in 48 of evaluable patients; seven patients had minor tumor regression. Twelve patients with stable disease were treated for >/=16 weeks. No trend was observed correlating tumor molecular alteration with antitumor activity. CONCLUSION: SAR245409 had a manageable safety profile, demonstrated reduced PI3K and mTORC1/mTORC2 pathway signaling and was associated with clinically relevant stable disease.

UR - http://clincancerres.aacrjournals.org/content/20/9/2445.full.pdf

U2 - 10.1158/1078-0432.CCR-13-2403

DO - 10.1158/1078-0432.CCR-13-2403

M3 - Article

VL - 20

SP - 2445

EP - 2456

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -